Key Takeaways
- Moderna has reached a $950 million upfront settlement with Arbutus Biopharma and Genevant Sciences, ending patent litigation over COVID vaccine technology.
- An additional $1.3 billion payment could be required if Moderna’s pending federal appeal is unsuccessful.
- This marks the pharmaceutical industry’s largest patent settlement ever and ranks second across all sectors.
- Following the announcement, Moderna’s stock surged 8.7% in after-hours trading, reaching $54.15.
- The company projects cash reserves of $4.5–$5 billion by the end of 2026, with overall liquidity reaching up to $5.9 billion.
Moderna has brought its protracted patent dispute to a close — and investors responded enthusiastically.
On Tuesday evening, the biotech firm revealed its agreement to pay $950 million upfront to Arbutus Biopharma (ABUS) and Genevant Sciences, a private entity, settling all worldwide patent litigation related to its Spikevax and mResvia vaccines.
The legal battle revolved around lipid nanoparticle (LNP) delivery systems, a crucial technology for delivering mRNA into cells. Arbutus and Genevant alleged that Moderna utilized their proprietary LNP technology without proper authorization.
In contrast, Arbutus shares declined 11% to $4.20 during after-hours trading following the announcement.
The $950 million settlement will be recognized as a financial charge in the first quarter of 2026, with the full amount disbursed as a single payment in the third quarter. Following this payment, Moderna will have no ongoing royalty obligations.
However, there’s a conditional element. Moderna is currently challenging a federal circuit court decision, asserting limited liability under its role as a government contractor. Should the appeal fail, the company has committed to paying an additional $1.3 billion within a 90-day window.
The maximum potential liability of $2.25 billion remains significantly lower than initial projections. According to William Blair analysts, market participants had anticipated potential liabilities approaching $5 billion, which would have created substantial liquidity challenges.
Under the settlement terms, Genevant is providing Moderna with a worldwide non-exclusive license for its LNP delivery technology applicable to specific mRNA vaccines. Additionally, Genevant has committed to refraining from future litigation against Moderna concerning particular patents.
Impact on Moderna’s Financial Standing
Factoring in the settlement, Moderna anticipates concluding 2026 with cash and cash equivalents ranging from $4.5 billion to $5 billion. The company maintains access to approximately $900 million through an existing credit line, pushing total anticipated liquidity to between $5.4 billion and $5.9 billion.
CEO Stéphane Bancel emphasized that this agreement eliminates uncertainty, enabling the organization to concentrate on future objectives.
Bancel projects that Moderna will achieve revenue growth again by late 2026. The firm is pursuing regulatory approval for its combined flu-COVID vaccine alongside a standalone influenza vaccine within the current year.
Upcoming Pipeline Developments and Clinical Data
Multiple clinical trial outcomes in oncology and rare disease programs are anticipated throughout 2026, which William Blair analysts identified as prospective “new long-term growth drivers.”
The settlement eliminates a significant concern that had been weighing on the stock. Moderna’s mRNA technology platform serves as the foundation for its extensive pipeline extending beyond COVID-19 applications.
Arbutus and Genevant characterized the agreement as the pharmaceutical industry’s largest documented patent settlement and the second-largest settlement recorded across any sector.
Genevant CEO James Heyes described the outcome as “enormously gratifying” recognition of the company’s role in addressing the pandemic.
Moderna’s stock has climbed more than 60% during the past year, significantly outperforming the S&P 500’s approximately 17% increase over the same period.
The $950 million lump-sum payment is scheduled for the third quarter of 2026.
